Skip to main content
Retour
PGEN logo

Precigen, Inc.

Qualité des données : 100%
PGEN
NASDAQ Healthcare Biotechnology
3,10 €
▼ 0,03 € (-0,96%)
Cap. Boursière : 931,33M
Fourchette du Jour
3,04 € 3,25 €
Fourchette 52 Semaines
1,11 € 5,47 €
Volume
5 959 675
Moyenne 50J / 200J
4,17 € / 3,40 €
Clôture Précédente
3,13 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -2,2 0,2
P/B 44,5 3,0
ROE % -1446,0 3,6
Net Margin % -4436,6 3,8
Rev Growth 5Y % -9,2 9,9
D/E 4,7 0,2

Objectif de Cours des Analystes

Hold
6,00 € +93.5%
BPA Prévisionnel
-0,18 €
CA Est.
98,61M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 0,63 €
0,49 € – 0,77 €
451,33M 1
FY2028 0,38 €
0,30 € – 0,47 €
331,11M 1
FY2027 0,07 €
-0,01 € – 0,16 €
205,37M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-25 -0,08 € -0,08 € -0,1%
2025-11-13 -0,08 € -0,11 € -37,5%
2025-08-12 -0,14 € -0,11 € +21,4%
2025-05-14 -0,08 € -0,07 € +12,5%
2025-03-19 -0,06 € -0,04 € +33,3%
2024-11-14 -0,08 € -0,09 € -12,5%
2024-08-14 -0,09 € -0,10 € -11,1%
2024-05-14 -0,09 € -0,10 € -11,1%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue declined -9,23% annually over 5 years
Debt/Equity of 4,70 — high leverage
Negative free cash flow of -87,83M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 155,96%
Capital efficient — spends only 0,00% of revenue on capex
ROIC of 0,00% — low return on invested capital

Croissance

Revenue Growth (5Y)
-9,23%
Revenue (1Y)146,73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-1446,02%
ROIC0,00%
Net Margin-4436,62%
Op. Margin0,00%

Sécurité

Debt / Equity
4,70
Current Ratio3,09
Interest Coverage0,00

Valorisation

P/E Ratio
-2,17
Forward P/EN/A
P/B Ratio44,54
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 146,73% Revenue Growth (3Y) 24,73%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -9,23% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9,68M Net Income (TTM) -429,64M
ROE -1446,02% ROA -276,29%
Gross Margin 0,00% Operating Margin 0,00%
Net Margin -4436,62% Free Cash Flow (TTM) -87,83M
ROIC 0,00% FCF Growth (3Y) N/A
Safety
Debt / Equity 4,70 Current Ratio 3,09
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,17 Forward P/E N/A
P/B Ratio 44,54 P/S Ratio 96,17
PEG Ratio 0,00 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 9,44 Fwd Earnings Yield N/A
FCF Yield -9,43%
Market Cap 931,33M Enterprise Value 999,38M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,68M 3,93M 6,23M 26,91M 14,27M
Net Income -429,64M -126,24M -95,90M 28,32M -92,17M
EPS (Diluted) -1,37 -0,47 -0,39 -0,33 -0,47
Gross Profit 0,0 -342 000,0 106 000,0 20,57M -39,41M
Operating Income 0,0 -135,03M -99,76M -75,73M -91,95M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 155,51M 145,27M 151,04M 215,98M 359,86M
Total Liabilities 134,59M 106,75M 32,55M 89,72M 252,51M
Shareholders' Equity 20,91M 38,51M 118,50M 126,26M 107,35M
Total Debt 98,29M 5,50M 7,10M 51,42M 190,07M
Cash & Equivalents 30,23M 29,52M 7,58M 4,86M 36,42M
Current Assets 115,24M 102,41M 68,76M 118,16M 156,63M
Current Liabilities 37,31M 21,52M 22,99M 78,65M 34,65M